“atai’s management believes these data support the concept of at-home use of PCN-101 in future studies.” – Christian Angermayer
Yesterday we reported on results from atai’s new Phase 1 study of its PCN-101 ketamine compound. The drug had disappointing trial results back in January and the company has been researching where to go next with one of its (formerly?) most promising drugs.
atai announced results from Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The Phase 1 study looked at PCN-101 delivered subcutaneously compared to PCN-101 delivered intravenously (the previous trial with lackluster results was done intravenously).
Results were promising, showing that subcutaneous injection (directly into the body, like an injection into the arm) could have more efficient results than IV delivery.
But what do these early results mean for the PCN-101 program? This is what ATAI investors have been wondering since January.
atai founder Christian Angermayer gave some clarification on this, giving hope that PCN-101 could be revived as an at-home alternative to Spravato.
Will atai now invest in new trials? Go the partnership route?
See his full comments below.
After some setbacks for @atai_life's R-Ketamine (PCN-101) earlier this year, I am very happy to see good news today.
Some background: We know that Ketamine works for depression. The approval of J&J’s Spravato/S-Ketamine and a growing market for Ketamine clinics (using both…
— Christian Angermayer (@C_Angermayer) August 9, 2023
